H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $169 from $73 and keeps a Buy rating on the shares. The firm says the results from the RASolute 302 trial de-risk the ongoing and planned Phase 3 trials for daraxonrasib. Daraxonrasib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and overall survival, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines files to sell $750M of common stock
- Revolution Medicines files to sell $250M of convertible senior notes
- Morning News Wrap-Up 4/13/26: Today’s Biggest Stock Market Stories!
- Bar remains unchanged for Erasca after Revolution’s ‘clear win,’ says Jefferies
- Erasca drops 9% to $15.54 after Revolution pancreatic cancer data